Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931423 | 0.88 | PDE4B (0.50) | ALDH1A1SIGMAR1HRH3SMN1; SMN2HTT | |
| SCHEMBL2930004 | 0.85 | KDM4E (0.48) | ALDH1A1KDM4ESIGMAR1POLB | |
| SCHEMBL2924514 | 0.85 | ALDH1A1 (0.70) | ALDH1A1KDM4ESIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL5591825 | 0.83 | KDM4E (0.50) | ALDH1A1KDM4ESIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL3169406 | 0.76 | SIGMAR1 (0.79) | ALDH1A1KDM4ESIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL29447340 | 0.76 | SIGMAR1 (0.79) | ALDH1A1KDM4ESIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL8276926 | 0.76 | SLC6A2 (0.49) | CYP2D6CYP2C19 | |
| SCHEMBL8278910 | 0.76 | SLC6A2 (0.49) | CYP2D6CYP2C19 | |
| SCHEMBL21645338 | 0.76 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL1890670 | 0.75 | SIGMAR1 (0.77) | ALDH1A1KDM4ESIGMAR1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
| EP-2121616-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | Campiani, Giuseppe (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008101891-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | ALDH1A1 4027/4885KDM4E 315/4885SIGMAR1 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.